432 related articles for article (PubMed ID: 28025949)
1. Targeted Nanoparticles for the Treatment of Alzheimer's Disease.
MartÃn-Rapun R; De Matteis L; Ambrosone A; Garcia-Embid S; Gutierrez L; de la Fuente JM
Curr Pharm Des; 2017; 23(13):1927-1952. PubMed ID: 28025949
[TBL] [Abstract][Full Text] [Related]
2. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease.
Zhang C; Chen J; Feng C; Shao X; Liu Q; Zhang Q; Pang Z; Jiang X
Int J Pharm; 2014 Jan; 461(1-2):192-202. PubMed ID: 24300213
[TBL] [Abstract][Full Text] [Related]
3. Targeted drug delivery across the blood brain barrier in Alzheimer's disease.
Rocha S
Curr Pharm Des; 2013; 19(37):6635-46. PubMed ID: 23621533
[TBL] [Abstract][Full Text] [Related]
4. Neurotherapeutic applications of nanoparticles in Alzheimer's disease.
Sahni JK; Doggui S; Ali J; Baboota S; Dao L; Ramassamy C
J Control Release; 2011 Jun; 152(2):208-31. PubMed ID: 21134407
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's Disease Targeted Nano-Based Drug Delivery Systems.
Altinoglu G; Adali T
Curr Drug Targets; 2020; 21(7):628-646. PubMed ID: 31744447
[TBL] [Abstract][Full Text] [Related]
6. The Blood Brain Barrier and its Role in Alzheimer's Therapy: An Overview.
Jakki SL; Senthil V; Yasam VR; Chandrasekar MJN; Vijayaraghavan C
Curr Drug Targets; 2018; 19(2):155-169. PubMed ID: 28606049
[TBL] [Abstract][Full Text] [Related]
7. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
Agrawal M; Saraf S; Saraf S; Antimisiaris SG; Chougule MB; Shoyele SA; Alexander A
J Control Release; 2018 Jul; 281():139-177. PubMed ID: 29772289
[TBL] [Abstract][Full Text] [Related]
8. Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer's disease.
Arora D; Bhatt S; Kumar M; Vattikonda HDC; Taneja Y; Jain V; Joshi V; Gali CC
Curr Pharm Des; 2020; 26(27):3281-3299. PubMed ID: 32228421
[TBL] [Abstract][Full Text] [Related]
9. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
Brain Res; 2008 Mar; 1200():159-68. PubMed ID: 18291351
[TBL] [Abstract][Full Text] [Related]
10. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease.
Roney C; Kulkarni P; Arora V; Antich P; Bonte F; Wu A; Mallikarjuana NN; Manohar S; Liang HF; Kulkarni AR; Sung HW; Sairam M; Aminabhavi TM
J Control Release; 2005 Nov; 108(2-3):193-214. PubMed ID: 16246446
[TBL] [Abstract][Full Text] [Related]
11. Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier.
Banks WA
Adv Drug Deliv Rev; 2012 May; 64(7):629-39. PubMed ID: 22202501
[TBL] [Abstract][Full Text] [Related]
12. The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer's disease.
Zhang C; Zheng X; Wan X; Shao X; Liu Q; Zhang Z; Zhang Q
J Control Release; 2014 Oct; 192():317-24. PubMed ID: 25102404
[TBL] [Abstract][Full Text] [Related]
13. Recent Trends in Nano-Particulate Carriers for the Diagnosis and Treatment of Alzheimer's Disease.
Mazahir F; Yadav AK
CNS Neurol Disord Drug Targets; 2023; 22(4):477-499. PubMed ID: 35450536
[TBL] [Abstract][Full Text] [Related]
14. Advancements in nanotherapeutics for Alzheimer's disease: current perspectives.
Harilal S; Jose J; Parambi DGT; Kumar R; Mathew GE; Uddin MS; Kim H; Mathew B
J Pharm Pharmacol; 2019 Sep; 71(9):1370-1383. PubMed ID: 31304982
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticlized System: Promising Approach for the Management of Alzheimer's Disease through Intranasal Delivery.
Bahadur S; Sachan N; Harwansh RK; Deshmukh R
Curr Pharm Des; 2020; 26(12):1331-1344. PubMed ID: 32160843
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders.
Sim TM; Tarini D; Dheen ST; Bay BH; Srinivasan DK
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842530
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticles Based Intranasal Delivery of Drug to Treat Alzheimer's Disease: A Recent Update.
Pandey M; Choudhury H; Verma RK; Chawla V; Bhattamisra SK; Gorain B; Raja MAG; Amjad MW
CNS Neurol Disord Drug Targets; 2020; 19(9):648-662. PubMed ID: 32819251
[TBL] [Abstract][Full Text] [Related]
18. Nanotherapeutics for Alzheimer's disease (AD): Past, present and future.
Fazil M; Shadab ; Baboota S; Sahni JK; Ali J
J Drug Target; 2012 Feb; 20(2):97-113. PubMed ID: 22023651
[TBL] [Abstract][Full Text] [Related]
19. Advances in developing therapeutic strategies for Alzheimer's disease.
Nguyen TT; Nguyen TTD; Nguyen TKO; Vo TK; Vo VG
Biomed Pharmacother; 2021 Jul; 139():111623. PubMed ID: 33915504
[TBL] [Abstract][Full Text] [Related]
20. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
